Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF MARCH 16, 2024 SAM #8145
SPECIAL NOTICE

Q -- Laboratory services for assay development and protein labeling services for the DNAPK project

Notice Date
3/14/2024 6:42:33 AM
 
Notice Type
Special Notice
 
NAICS
541714 — Research and Development in Biotechnology (except Nanobiotechnology)
 
Contracting Office
NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
 
ZIP Code
20892
 
Solicitation Number
75N95024Q00197
 
Response Due
3/21/2024 9:00:00 AM
 
Archive Date
04/05/2024
 
Point of Contact
Kaitlyn Landi, Phone: 3018271804
 
E-Mail Address
kaitlyn.landi@nih.gov
(kaitlyn.landi@nih.gov)
 
Description
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to AAT Bioquest Inc 5775 W Las Positas Blvd STE 100 Pleasanton, CA 94588 for Laboratory services for assay development and protein labeling services for the DNAPK project. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS The intended procurement is classified under NAICS 541714 Research and Development in Biotechnology with a Size Standard of 1000. � REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures. Contracts awarded using FAR Part 13�Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6�Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization). The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2022-08 dated October 22, 2022. DESCRIPTION OF REQUIREMENT PURPOSE AND OBJECTIVES: This requisition is to procure assay development and protein labeling services for the Therapeutics for Rare and Neglected Disease (TRND) laboratory. Purchase Description: Custom Services: AAT Bioquest has the technical acumen necessary to develop complex protein labeling, using a variety of approaches. As part of assay development, AAT will test different labeling methods with a variety of probe and protein pairs to obtain the highest possible signal to background, lowest CV, and overall best assay quality. i) Bioconjugation services. Labels depend on application and assay design, including but not limited to the following dyes: trFluor dyes (Eu, Tb), iFluor (647, TF5, APC) for TR-FRET labeling. Time-resolved fluorescence energy transfer involves a donor and acceptor fluorophore. Excitation of the donor will transfer energy to the acceptor if the two are in proximity. AAT uses trFluor technology for FRET labeling applications. AAT Bioquest will purchase commercial antibodies against DNAPK for this work. ii) Assay Development: Assay development requirements depend on specific applications and project assay design, but includes labeling and evaluating labeling protein pairs, and evaluating capabilities and performance (signal to background, CV, Z scores) of the agreed upon assay. Assays include: (1) Using above labeled antibodies to detect the TR-FRET signal as an indication of DNAPK activation (self-phosphorylation). (2) Select two best pairs of labeled antibodies that will be shipped to NCATS for testing in cell-based assay in NCATS. iii) Once NCATS team has tested the antibodies pairs from above in the cell based DNAPK assay and has decided the final pair of the antibodies, AAT Bioquest will purchase commercial antibodies to make large scale conjugation that ESTIMATED PERIOD OF PERFORMANCE: Period of performance is 6 weeks ARO CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, AAT Bioquest Inc 5775 W Las Positas Blvd STE 100 Pleasanton, CA 94588 is the only vendor in the marketplace that can provide the services required by NIDA . The intended source is: AAT Bioquest Inc 5775 W Las Positas Blvd STE 100 Pleasanton, CA 94588 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the solicitation number, 75N95024Q00197. Responses must be submitted electronically to Kaitlyn Landi, Contract Specialist, at kaitlyn.landi@nih.gov and KJ Shaikh, Contracting Officer, at kj.shaikh@nih.gov.� U.S. Mail and fax responses will not be accepted.
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/4c2dd14addeb48589d146fa2c87ff2c8/view)
 
Record
SN06996599-F 20240316/240314230047 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.